Abstract
The clinical outcomes of hepatocellular carcinoma still lag behind those of other common cancers such as colorectal and breast cancers. Specifically, there is currently no adjuvant or neoadjuvant therapy in HCC. Pivotal clinical trials are thus needed to address important management issues in HCC. The last few years has seen positive phase III trials with systemic therapy in advanced HCC including immunotherapy combination. These has thus provided impetus for a range of clinical trials in HCC addressing adjuvant and neoadjuvant therapies in resected HCC, loco-regional therapy combinations in intermediate/locally advanced HCC and systemic combination therapies in advanced HCC. Current pivotal prospective multinational trials for these indications are discussed.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
